BS Summary: This article contains 28 faulty reasoning types, including Hasty Generalization, Biased Writer Voice, and Appeal to Emotion, with Negativity Bias as the most egregious example at 50.3% saturation with 428 hits. Analysis detected 2,690 faulty-reasoning hits from 851 analyzed words, generating a BS Score of 62.7% and a BS Rank of 70% (6,713 of 21,887 articles). This article is worse (more manipulative) than 69.30% of the article peer group.
Advertisements for personalized GLP-1 weight-loss drugs are now as pervasive as they are dangerous.
There’s already a robust national debate about direct-to-consumer pharmaceutical advertising.
But regardless of where you fall in that debate, everyone can agree: Ads that fail to follow even basic disclosure rules — and target vulnerable people with misleading health claims — deserve serious scrutiny and enforcement.
That concern is especially urgent in the booming market for GLP-1s.
Telehealth companies and mass-compounding entities are driving widespread promotion of compounded GLP-1s, using marketing that can obscure the fact that these products are not FDA -approved.
Transparency is a priority that this administration has rightly championed across healthcare.
It’s time the FDA and Congress held compounded GLP-1 marketing to that same standard — before more patients are misled about what they’re putting into their bodies.
Compounding itself is a legitimate medical practice that allows pharmacists to tailor treatments for patients with specific needs or to fill gaps during drug shortages.
But because they’re produced individually or for temporary emergencies, they don’t undergo the FDA’s rigorous review process for safety, effectiveness, or quality.
Compounded products were never meant to become a mass-market alternative to FDA-approved drugs, deceptively sold through targeted social media ads and telehealth platforms to anyone willing to pay.
As these weight loss products flood people’s screens, most have no idea what they’re being sold.
Young people and those who have eating disorders are among the most exposed — and they’re least equipped to recognize the difference between a polished ad and a legitimate medical treatment.
When you see an ad for an FDA-approved drug on TV , the law requires disclosure of risks and side effects, substantiated claims, and agency oversight.
Compounded drug ads face none of those requirements.
And on social media — where these ads are most concentrated and dangerous — enforcement is essentially nonexistent from either regulators or the platforms.
Consider the 2025 Super Bowl .
Hims & Hers ran a primetime ad promoting its compounded GLP-1 to more than 100 million viewers without disclosing that the product was compounded and had not been FDA-reviewed.
Without fine print or safety warnings, it may have appeared more reassuring than ads for drugs that actually are regulated.
The campaign was seen online millions of times even after the Super Bowl.
Some ads go further, promoting add-on ingredients such as vitamin B12 and amino acids as personalized, premium clinical enhancements.
There’s no evidence these additions improve outcomes or safety .
Mainly, they help telehealth companies sidestep restrictions on mass-producing knockoff versions of FDA-approved drugs.
These companies are far from blameless.
But why would they prioritize patient safety over profits when there’s no accountability, and when the platforms distributing their ads profit from the same engagement?
Take Jimmie Wilson of Kentucky as a harrowing example.
She’d heard about the benefits of GLP-1s, talked to her doctor, and got a prescription filled at a compounding pharmacy — exactly as a careful patient would.
Yet Wilson was never given the full picture: She was sold something less safe than an FDA-approved GLP-1 without adequate warning about the risks.
And about four weeks after her first injection, her liver enzymes spiked to dangerous levels.
Her doctor sent her straight to the emergency room, where she was placed at the top of the transplant list.
Wilson’s story underscores just how serious the consequences can be when transparency breaks down.
The FDA has received hundreds of adverse event reports tied to compounded semaglutide and tirzepatide.
Each patient likely had no idea they were taking something never reviewed for safety or quality.
The agency’s warning letters to 30 telehealth companies this year were a start.
But they mean little when the financial incentive to advertise aggressively far outweighs the reputational cost of receiving a warning letter.
Social media platforms cannot be depended on to police these misleading advertisers.
If they’re willing to turn a blind eye to people selling deadly fake pills with fentanyl , they aren’t going to crack down when it comes to deceptively marketed weight loss medications.
The onus lies with federal regulators to intervene.
The FDA should require plain-language disclosure in marketing, both online and offline, that a product is compounded and has not been evaluated by the agency.
When companies present a compounded product as equivalent to an approved drug, the FDA should declare it misbranded and use injunctions to stop them from marketing that way.
WHY ARE TRIAL LAWYERS PRACTICING MEDICINE IN OUR LIVING ROOMS?
The authority exists.
Congress should strengthen it — and make clear the expectation is enforcement.
Not every person harmed by what they see online will show up in an adverse event report.
Federal leaders should ensure Americans — especially young people and those already at risk — know what they’re putting in their bodies before it’s too late.
Eric Feinberg is vice president of content moderation at the Coalition for a Safer Web and the founder of the Global Intellectual Property Enforcement Center, which developed a patented AI-driven machine-learning tool to detect and analyze harmful content at scale.
Speakers
Loading…
Loading…
Loading…
Loading…
Analysis
Hover over highlighted words in the article to view the associated bias or fallacy analysis.